Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Auteur(s) :
Montella M., Ciliberto G., Quagliariello V., Rossetti S., Cavaliere C., Palo RD., Lamantia E., Castaldo L., Nocerino F., Ametrano G., Cappuccio F., Malzone G., Montanari M., Vanacore D., Romano FJ., Piscitelli R., Iovane G., Pepe MF., Berretta M., D'Aniello C., Perdonà S., Muto P., Botti G., Veneziani BM., De Falco F., Maiolino P., Caraglia M., Iaffaioli RV., Facchini G.
Date :
Mai, 2017
Source(s) :
Oncotarget. #2:18 p30606-30616
Adresse :
Progetto ONCONET2.0 - Linea progettuale 14 per l'implementazione della prevenzione e diagnosi precoce del tumore alla prostata e testicolo - Regione Campania, Italy.

Sommaire de l'article

This review summarizes the main pathophysiological basis of the relationship between metabolic syndrome, endocrine disruptor exposure and prostate cancer that is the most common cancer among men in industrialized countries. Metabolic syndrome is a cluster of metabolic and hormonal factors having a central role in the initiation and recurrence of many western chronic diseases including hormonal-related cancers and it is considered as the world's leading health problem in the coming years. Many biological factors correlate metabolic syndrome to prostate cancer and this review is aimed to focus, principally, on growth factors, cytokines, adipokines, central obesity, endocrine abnormalities and exposure to specific endocrine disruptors, a cluster of chemicals, to which we are daily exposed, with a hormone-like structure influencing oncogenes, tumor suppressors and proteins with a key role in metabolism, cell survival and chemo-resistance of prostate cancer cells. Finally, this review will analyze, from a molecular point of view, how specific foods could reduce the relative risk of incidence and recurrence of prostate cancer or inhibit the biological effects of endocrine disruptors on prostate cancer cells. On the basis of these considerations, prostate cancer remains a great health problem in terms of incidence and prevalence and interventional studies based on the treatment of metabolic syndrome in cancer patients, minimizing exposure to endocrine disruptors, could be a key point in the overall management of this disease.

Source : Pubmed